Michael H. Carrel: 2025 was an exceptional year at AtriCure, Inc. with achievements across our business. This trial is evaluating the benefit of our AtriClip devices on non-AFib patients undergoing ...
If you are wondering whether KLA's share price still reflects good value after a strong run, you are not alone. This article will help you frame that question clearly. The stock closed at US$1,470.19, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results